The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.
Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle invasive bladder cancer (NMIBC).
The drug maker announced 10 January positive topline results from the Phase III CREST trial of sasanlimab combined with Bacillus...
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
